

Contents

Cytogenetic alterations in prostate cancer	1
<i>G. Sauter</i>	
The regulation of prostatic growth	9
<i>K. Griffiths</i>	
Current concepts of oncogenes in prostate cancer	23
<i>D. M. Peehl</i>	
Tumour suppressor genes in prostate cancer	31
<i>S. F. Brewster</i>	
The use of differential display PCR for the detection of new tumor suppressor genes in prostate cancer	43
<i>Ch. P. Pilarsky</i>	
Molecular alterations associated with prostate cancer development	53
<i>M. J. G. Bussemakers, J. A. Schalken</i>	
Dysfunction of the cell-cell adhesion complex in lethal prostate cancer	65
<i>R. Paul, W. B. Isaacs, G. S. Bova</i>	
Heparan sulfate proteoglycans and prostate cancer: a conceptual framework	71
<i>D. H. J. Schamhart, K.-H. Kurth</i>	
Androgen receptor mutations in prostate cancer	81
<i>H. Klocker, Z. Culig, A. Hobisch, A. Hittmair, G. Bartsch, H. Peterziel, A. C. B. Cato</i>	
Antiandrogen binding to androgen receptors and the consequences	89
<i>B. J. A. Furr</i>	
Expression of the MDR1 gene in prostate carcinoma	101
<i>M. J. Siegmund, B. Schummer, A. Steidler, M. Greschner, K.-U. Köhrmann, P. Alken</i>	
Human prostate cancer progression models and therapeutic intervention	107
<i>L. W. K. Chung, C. Kao, R. A. Sikes, H. E. Zhau</i>	
Tumor angiogenesis: the VEGF signalling system is a novel target for prostate cancer therapy	115
<i>D. Marmé</i>	

Antimetastatic approaches to therapy of prostate cancer	125
<i>R. Heicappell</i>	
Intermittent androgen supression: rationale and clinical experience	133
<i>M. Gleave, N. Bruchovsky, S. L. Goldenberg, P. Rennie</i>	
Resistance to drug therapy in cancer: gene therapy approaches to overcome anticancer drug resistance	145
<i>Th. Licht</i>	
PSA RT-PCR: current status and future potential	155
<i>W. J. Ellis, R. L. Vessella, S. W. Melchior, P. H. Lange</i>	
Special aspects of PSMA and PSA RT-PCR for the detection of disseminated prostate cells	161
<i>B. Schmidt, M. Bendhack, R. Ackermann, B. J. Schmitz-Dräger</i>	
Molecular forms of PSA, PSA density, age-/race-specific reference ranges, and PSA velocity	169
<i>M. C. Beduschi, R. Beduschi, J. E. Oesterling</i>	
Reverse transcriptase-polymerase chain reaction assays used for molecular stag- ing of prostate cancer patients	181
<i>C. A. Olsson, R. Buttyan</i>	
Concluding remarks	201
<i>J. E. Altwein</i>	